Gene Therapy Loses Luster as Investors Eye Quicker Returns From Weight-Loss Drugs
In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...
Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
Editas Medicine Announces Chief Financial Officer Transition
Erick J. Lucera to Step Down as CFO to pursue another opportunitySenior Vice President of Finance Amy Parison Appointed CFOCAMBRIDGE, Mass., ...
DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...
DelveInsight Business Research, LLP: DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...